{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-24-020439","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.198266+00:00","generated_at":"2026-05-29T04:08:18.184377+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alzamend Neuro reports Q2 fiscal 2025: cash $4.1M, equity $3.8M, five Phase II trials planned in 2025","bullets":["Net cash from financing $8.3M for six months ended Oct 31, 2024; stockholder equity improved to $3.8M from a $2.6M deficit.","Cash increased to $4.1M from $0.4M; total liabilities reduced to $1.3M from $3.2M at April 30, 2024.","Regained Nasdaq compliance; entered $25M preferred stock/warrant agreement and $6.5M ATM facility.","AL001 (lithium cocrystal) to initiate five Phase II trials in 2025 with Mass General for Alzheimer's, BD, MDD, PTSD.","ALZN002 immunotherapy trial resumption planned for 2025 after re-engaging a new CRO."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-24-020439","json":"https://secwatch.observer/filing/0001214659-24-020439.json","markdown":"https://secwatch.observer/filing/0001214659-24-020439.md","text":"https://secwatch.observer/filing/0001214659-24-020439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924020439/0001214659-24-020439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924020439/d12122438k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:08:18.184377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}